Puma Biotechnology to Present at the B. Riley Oncology Investor Conference
Puma Biotechnology (NASDAQ: PBYI) announced that CEO Alan H. Auerbach will present an overview of the company at the B. Riley Oncology Investor Conference on January 21, 2021. The presentation will be available for replay on the company’s website for 30 days starting at approximately 1:30 p.m. PST. Puma is focused on developing innovative cancer care solutions, including NERLYNX® (neratinib), which has FDA approval for treating early-stage and advanced HER2-positive breast cancer. For more information, visit www.pumabiotechnology.com.
- None.
- None.
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company on January 21, 2021 at the virtual B. Riley Oncology Investor Conference. A replay of the presentation will be available for 30 days beginning at approximately 1:30 p.m. PST on January 21, 2021 on the Company’s website at www.pumabiotechnology.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.
Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005149/en/
FAQ
What will Alan H. Auerbach discuss at the B. Riley Oncology Investor Conference?
When can I watch the replay of Puma Biotechnology's presentation?
What is NERLYNX and its significance?
Where can I find more information about Puma Biotechnology?
What is the stock symbol for Puma Biotechnology?
